EcoDrugPlus

Porcupine O-Acyltransferase Like

Ensembl ID : ENSACIG00000013683
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSACIG00000016984
Gene Symbol: KCNMA1
1 Cross references
227 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSACIG00000024495
Gene Symbol: KCNMA1
1 Cross references
243 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSACIG00000009179
Gene Symbol: KCNN4
1 Cross references
190 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSACIG00000005070
Gene Symbol: KCNK2B
1 Cross references
214 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSACIG00000013892
Gene Symbol: KCNK3A
1 Cross references
203 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSACIG00000002810
Gene Symbol: KCNK9
1 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSACIG00000021056
Gene Symbol: KCNJ11
1 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSACIG00000000838
Gene Symbol: KCNJ2
1 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSACIG00000021122
Gene Symbol: KCNJ2A
1 Cross references
201 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSACIG00000000634
Gene Symbol: KCNJ3
1 Cross references
222 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSACIG00000021666
Gene Symbol: KCNJ5
1 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).